Candriam S.C.A. Reduces Holdings in Insmed, Inc. $INSM

Candriam S.C.A. lessened its position in shares of Insmed, Inc. (NASDAQ:INSM) by 3.7% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 438,688 shares of the biopharmaceutical company’s stock after selling 16,820 shares during the quarter. Candriam S.C.A.’s holdings in Insmed were worth $44,151,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. increased its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 221 shares during the last quarter. ORG Partners LLC grew its holdings in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank acquired a new stake in shares of Insmed during the 2nd quarter worth about $28,000. FNY Investment Advisers LLC purchased a new stake in Insmed in the 2nd quarter valued at about $33,000. Finally, LRI Investments LLC acquired a new position in Insmed in the second quarter valued at about $59,000.

Insmed Price Performance

Insmed stock opened at $194.39 on Thursday. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $197.08. The firm has a market cap of $41.46 billion, a PE ratio of -34.04 and a beta of 1.05. The company’s 50 day moving average is $160.42 and its two-hundred day moving average is $118.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm’s revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. On average, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider owned 36,461 shares of the company’s stock, valued at $5,303,252.45. This trade represents a 67.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 6,865 shares of Insmed stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the transaction, the chief executive officer owned 233,924 shares of the company’s stock, valued at $30,035,841.60. The trade was a 2.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 179,787 shares of company stock worth $26,428,149 over the last three months. Company insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on INSM shares. Jefferies Financial Group lifted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Stifel Nicolaus lifted their target price on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. UBS Group boosted their target price on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company upped their price target on Insmed from $171.00 to $217.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $173.29.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.